Humacyte Inc (HUMAW)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Humacyte Inc (HUMAW) is down 41.3% since the beginning of the year. At $0 per share, HUMAW is trading 90.8% below its 52-week high of $1. Investors who bought $1,000 worth of HUMAW shares 5 years ago would now be looking at an investment worth $22.

Humacyte Inc (HUMAW) has returned -41.30% so far this year and -89.62% over the past 12 months.

Based on dividend-adjusted daily data since Nov 24, 2020, HUMAW's average daily return is +0.26%, while the average monthly return is +4.01%. At this rate, an investment would double in approximately 1.5 years.

Historically, 46% of months were positive and 54% were negative. The best month was May 2024 with a return of +261.2%, while the worst month was Mar 2025 at -64.8%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 5 months.

On a daily basis, HUMAW closed higher 44% of trading days. The best single day was Feb 17, 2021 with a return of +128.0%, while the worst single day was Aug 11, 2025 at -51.6%.

Humacyte Inc has an annualized alpha of 51.01%, beta of 1.68, and R2 of 0.03 versus S&P 500 Index. Calculated based on daily prices since November 25, 2020.

• This stock participated in 234.90% of S&P 500 Index downside but only 55.17% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.03 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

HUMAW ranks 15 for risk / return — in the bottom 15% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.

The table below present risk-adjusted performance metrics for Humacyte Inc (HUMAW) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Humacyte Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Humacyte Inc was 98.82%, occurring on Jun 2, 2026. The portfolio has not yet recovered.

The current Humacyte Inc drawdown is 98.82%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Humacyte Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Humacyte Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.